跳至主要内容
临床试验/NCT04763876
NCT04763876已完成4 期

Comparison of Intramuscular Ketorolac at Two Single-Dose Regimens for Treatment of Acute Musculoskeletal Pain in a Military Emergency Department: A Randomized Controlled Non-Inferiority Trial

William Beaumont Army Medical Center1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2020年6月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
110
试验地点
1
主要终点
Mean Difference of Visual Analog Scale Scores

研究概览

简要总结

The purpose of this study was to evaluate a single 15 mg intramuscular (IM) dose of ketorolac for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK pain in a military emergency department (ED) that services Department of Defense (DoD), Department of Veteran Affairs (VA), and foreign military beneficiaries

详细描述

The primary purpose of this study is to evaluate a single 15 mg IM dose of ketorolac for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK pain in a military ED that services Department of Defense (DoD), Department of Veteran Affairs (VA), and foreign military beneficiaries. The authors chose to evaluate 15 mg rather than the previously identified 10 mg dose for ease of administration as ketorolac is manufactured in 15 mg/mL, 30 mg/mL, and 60 mg/2mL vials in the U.S. The dose of ketorolac served as the primary independent variable for the study and the change in Visual Analog Scale (VAS) score served as the dependent variable. Prescribing the minimally effective doses of NSAIDs is pertinent to prevent and reduce the number of adverse events. Thus, the secondary outcome assessed for the dose-dependence of subjective and objective adverse events with ketorolac.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

The patient was unaware of the dosage of ketorolac they received.

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Tricare beneficiaries between 18-55 years of age
  • Triaged as Emergency Severity Index 4 or 5
  • Presenting to the William Beaumont Army Medical Center Emergency Department with a chief complaint of acute MSK pain (i.e., general muscular, neck, back, shoulder, arm, forearm, elbow, wrist, finger, hip, knee, thigh, leg, ankle, foot, or digits)
  • Pain intensity of 20 mm or greater on a standard 100 mm visual analog scale
  • Who the attending provider concurred with ketorolac IM administration for analgesia.

排除标准

  • Body weight less than 50 kg (110 lbs.)
  • Younger than 18 or older than 55 years
  • Pregnant or breast feeding
  • History of: confirmed, unconfirmed, known, unknown, or suspected peptic ulcer disease, intestinal hemorrhage, renal insufficiency, hepatic insufficiency, cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, dark stools, bright red blood per rectum, hemoptysis, easy bruising, or high risk of bleeding
  • Unable to confidently convey or unknown medical history
  • Allergy or hypersensitivity to nonsteroidal anti-inflammatory drugs or aspirin
  • Systolic blood pressure <90 or >180 mmHg
  • Pulse rate <50 or >150 beats/min
  • Any over-the-counter or prescribed opioid and/or non-opioid analgesic medication (oral, per rectum, topical or parenteral) taken within 12 hours of ED presentation
  • Advised by any medical provider to not receive NSAIDs for any reason
  • Pain duration greater than 30 days (including acute on chronic pain)
  • Refusal to remain in the WBAMC ED for up to 60 minutes after injection of ketorolac
  • Patients currently taking anticoagulant medications
  • Concurrent use of medications which are contraindicated with concomitant NSAID use (drugs include aspirin, probenecid and pentoxifylline).

研究组 & 干预措施

15 mg ketorolac intramuscular

Active Comparator

Patients who received a single 15 mg dose of ketorolac administered intramuscularly

干预措施: Ketorolac Injection 15 mg (Drug)

60 mg ketorolac intramuscular

Active Comparator

Patients who received a single 60 mg dose of ketorolac administered intramuscularly

干预措施: Ketorolac Injection 60 mg (Drug)

结局指标

主要结局

Mean Difference of Visual Analog Scale Scores

时间窗: 60 minutes from administration of medication

The mean difference of Visual Analog Scale scores between the two treatment groups measured at 60-minutes. The Visual Analog Scale used measures from 0 mm to 100mm. A higher score represents more degree of change. 13 mm was used as the non-inferiority margin. A difference between the two groups less than 13 mm demonstrates that 15 mg is non-inferior to 60 mg.

次要结局

  • Mean Difference of Visual Analog Scale Scores(30 minutes from administration of medication)
  • Number of Participants With Adverse Events Related to the Administration of Ketorolac(At time of administration, 30 minutes after administration, and 60 minutes after administration.)

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Edna Rath

Human Protections Director

William Beaumont Army Medical Center

研究点 (1)

Loading locations...

相似试验